Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11242
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNayler, W Gen
dc.contributor.authorGu, X Hen
dc.date.accessioned2015-05-16T00:49:51Z
dc.date.available2015-05-16T00:49:51Z
dc.date.issued1990-11-20en
dc.identifier.citationThe American Journal of Cardiology; 66(18): 23H-27Hen
dc.identifier.govdoc2147359en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11242en
dc.description.abstractAlthough calcium antagonists were originally developed for use in the management of patients with angina pectoris, they are now used in the management of other cardiovascular disorders, including hypertension. More recently, the calcium antagonists have been under investigation for their potential protective role in atherosclerosis. Coupled with these new possibilities for therapeutic use are the development of new, long-acting, tissue-specific calcium antagonists. Amlodipine belongs to this group, and although it is a dihydropyridine-based calcium antagonist, its pharmacologic profile differs from that of other dihydropyridine-based calcium antagonists. Differences include: different pH optimum for receptor binding, different rates of association and dissociation, and differences in allosteric interaction with the diltiazem and verapamil binding sites. Amlodipine, when given orally to rabbits receiving a high-cholesterol diet, reduces atheroma formation. Evidence of its ability to protect the vasculature is provided by its ability to significantly increase (p less than 0.001) survival in stroke-prone hypertensive rats.en
dc.language.isoenen
dc.subject.otherAmlodipineen
dc.subject.otherAnimalsen
dc.subject.otherArteries.drug effectsen
dc.subject.otherArteriosclerosis.prevention & controlen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCalcium Channel Blockers.pharmacokinetics.pharmacology.therapeutic useen
dc.subject.otherCerebrovascular Disorders.prevention & controlen
dc.subject.otherFemaleen
dc.subject.otherHypertension.drug therapyen
dc.subject.otherMaleen
dc.subject.otherNifedipine.analogs & derivatives.pharmacokinetics.pharmacology.therapeutic useen
dc.subject.otherRabbitsen
dc.subject.otherRatsen
dc.subject.otherRats, Inbred Strainsen
dc.subject.otherSurvival Rateen
dc.titleProtecting the vasculature: an eye toward the future.en
dc.typeJournal Articleen
dc.identifier.journaltitleThe American journal of cardiologyen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages23H-27Hen
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2147359en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.